Cutrell James, Jodlowski Tomasz, Bedimo Roger
Department of Medicine, University of Texas Southwestern Medical Center, Dallas, USA.
Department of Pharmacy, VA North Texas Health Care System, Dallas, USA.
Ther Adv Infect Dis. 2020 Jan 20;7:2049936120901395. doi: 10.1177/2049936120901395. eCollection 2020 Jan-Dec.
Significant advances in the potency and tolerability of antiretroviral therapy (ART) have led to very high rates of virologic success for most who remain adherent to therapy. As a result, the life expectancy of people living with HIV (PLWH) has increased significantly. PLWH do, however, continue to experience a significantly higher risk of noninfectious comorbidities and chronic age-related complications, including cardiovascular disease and malignancies, which are now the biggest drivers of this excess morbidity and mortality. Therefore, in addition to virologic failure, the management of the treatment-experienced patient increasingly requires optimization of ART to enhance tolerability, avoid drug-drug interactions, and mitigate non-AIDS complications and comorbid conditions. This article will present principles of the management of virologic failure, poor immunologic recovery, and strategies for optimizing ART in the setting of virologic suppression.
抗逆转录病毒疗法(ART)在效力和耐受性方面取得了重大进展,这使得大多数坚持治疗的患者病毒学成功率非常高。因此,艾滋病毒感染者(PLWH)的预期寿命显著增加。然而,PLWH仍然面临非感染性合并症和与年龄相关的慢性并发症的显著更高风险,包括心血管疾病和恶性肿瘤,这些现在是这种额外发病率和死亡率的最大驱动因素。因此,除了病毒学失败外,对有治疗经验的患者的管理越来越需要优化ART,以提高耐受性、避免药物相互作用,并减轻非艾滋病并发症和合并症。本文将介绍病毒学失败、免疫恢复不良的管理原则,以及在病毒学抑制情况下优化ART的策略。